Impact of Diabetes Medications on Breast Cancer Biomarkers: A Dutch Study

Research Overview

Researchers in the Netherlands have explored the effects of standard diabetes medications on biomarkers in breast cancer tumors. This cohort study involved 300 Danish women and focused on the impact of insulin and metformin on breast cancer in diabetic patients.

Key Findings

The study revealed that metformin and other treatments for type 2 diabetes did not show any significant effect on breast tumors. However, it was noted that breast tumors in premenopausal women using insulin for type 1 diabetes exhibited a higher presence of IGF1R markers. Furthermore, insulin use across women of all ages was associated with an increased likelihood of p-mTOR markers. This finding is noteworthy, as IGF1R is a target for several cancer therapies.

Context and Importance

The rising incidence of both diabetes mellitus and breast cancer necessitates investigating the potential link between these two conditions. Diabetes mellitus occurs when the body fails to produce sufficient insulin or cannot effectively utilize the insulin produced by the pancreas. Some studies suggest that insulin may contribute to tumor growth through various pathways.

Study Details

A recent study published in BMC Cancer examined the presence and potential effects of insulin-related proteins in breast tumors. Approximately 300 women diagnosed with breast cancer were recruited from a hospital database. This cross-sectional study included women with type 1 or type 2 diabetes, as well as those without diabetes. Patients diagnosed with diabetes mellitus less than one year prior to their breast cancer diagnosis were excluded.

Protein Analysis

A breast pathologist assessed five proteins—p-ER, EGFR, p-ERK 1/2, p-mTOR, and IGF1R—expressed in the breast tissue tumors. Researchers analyzed these findings to evaluate any relationships between protein expression, diabetes mellitus, and treatments involving insulin and non-insulin antidiabetic medications such as metformin.

Results and Conclusion

The results indicated no significant difference in the expression levels of any of the five proteins between women with and without diabetes. However, women on insulin therapy demonstrated a higher expression of IGF1R and p-mTOR proteins in their breast tumors. These findings suggest a potential association between insulin use in diabetic women and the development of specific proteins in breast tumors. This critical research area warrants further investigation to clarify the relationship between diabetes mellitus and breast cancer, aiding clinicians in developing effective treatment plans for women facing these conditions.

Reference

Bronsveld HK et al. The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. BMC Cancer (2018) 18:224.